Journal
EXPERT OPINION ON DRUG SAFETY
Volume 6, Issue 5, Pages 609-621Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14740338.6.5.609
Keywords
adverse effects; cancer; paclitaxel; safety; toxicity
Categories
Ask authors/readers for more resources
Better known as Taxol (R) (Bristol-Myers Squibb), paclitaxel is the first member of the taxane family to be used in cancer chemotherapy. The taxanes exert their cytotoxic effect by arresting mitosis through microtubule stabilization, resulting in cellular apoptosis. The use of paclitaxel as a chemotherapeutic agent has become a broadly accepted option in the treatment of patients with ovarian, breast and non-small cell lung cancers, malignant brain tumors, and a variety of other solid tumors. However, significant toxicities, such as myelo-suppression and peripheral neuropathy, limit the effectiveness of paclitaxel-based treatment regimens. This review addresses the toxicities associated with paclitaxel treatment and describes existing and future strategies of paclitaxel administration directed at limiting these toxicities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available